Novo Nordisk A/S @ 2023-08-27

News Title: Wegovy helps reduce heart failure symptoms in obese people, study says
Description: The trial results add to Wegovy’s growing list of potential health benefits beyond shedding unwanted pounds.
News Sentiment: -0.15833333333333335 (Slightly Negative)

Novo Nordisk A/S

Sector: Healthcare

Industry: Biotechnology

Full Time Employees: 59337


Long Business Summary:

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Basic Chart

Novo Nordisk A/S
Novo Nordisk A/S

Technical Chart

Novo Nordisk A/S
Novo Nordisk A/S

Suggested Currency Pair: USD/NOK

Leave a Comment